Konruns(SH:603590) Xin Lang Cai Jing·2025-10-14 03:16Group 1 - The core point of the news is that Kangchen Pharmaceutical's stock has experienced a decline of 5.07% on October 14, with a cumulative drop of 7.7% over three consecutive days, leading to a market capitalization of 7.512 billion yuan [1] - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, focuses on innovative drug research and development, with its main business revenue composition being 70.77% from Suling, 29.15% from Salmon Calcitonin, and 0.09% from other sources [1] Group 2 - According to data, the Xinda Aoya Fund holds Kangchen Pharmaceutical as its tenth largest position, with 730,600 shares representing 3.38% of the fund's net value, resulting in a floating loss of approximately 1.8411 million yuan today and a total floating loss of 3.0247 million yuan during the three-day decline [2] - The Xinda Health China Mixed A Fund (003291) was established on August 18, 2017, with a current scale of 534 million yuan, achieving a year-to-date return of 26.2% and a one-year return of 24.88% [2]